膀胱移行细胞癌Survivin表达临床特征分析

Clinical feature of survivin expression in bladder transitional cell carcinomas

目的:探讨Survivin蛋白在不同病理类型及不同临床分期的膀胱移行细胞癌中的表达规律。方法:膀胱癌组为膀胱移行细胞癌44例肿瘤组织保存腊块,其中病理分级Ⅰ级16例、Ⅱ级16例、Ⅲ级12例;临床分期表浅型24例、浸润型20例;另取10例非肿瘤患者的正常膀胱黏膜做对照。采用免疫组织化学SABC染色法进行Survivin表达的定位和半定量检测。结果:正常对照组Survivin阳性表达率为0%(0/10),44例膀胱移行细胞癌中34例Survivin蛋白表达阳性,阳性率为77.3%(34/44),显著高于正常对照组。分项统计中,肿瘤病理分级Ⅰ级组(56.3%,9/16)、Ⅱ级组(87.5%,14/16)、Ⅲ级组(91.7%,11/12)及表浅型(79.2%,19/24)、浸润型(75.0%,15/20)Survivin表达阳性率均显著高于正常对照组。相关分析表明,Survivin表达与肿瘤病理分级密切相关(χ2=6.395,P<0.05),与临床分期无显著相关关系(χ2=0.108,P>0.05)。结论:Survivin异常表达在膀胱移行细胞癌的发生发展中起重要作用,Survivin表达检测可成为膀胱移行细胞癌预后指标之一。

Objective：To explore the expression regulation of survivin in bladder transitional cell carcinomas of different grade and different stage. Methods：Forty four specimens from patients with transitional cell carcinonma of bladder were included in this experiment. Among them, 16 cases were in grade Ⅰ , 16 in grade Ⅱ and 12 in grade Ⅲ. Classified by clinical stage, 24 cases were superficial type, 20 invasive type. Ten normal specimens of mucous membrane of urinary bladder were included in the normal group. The expression of survivin was detected with im munohistochemistry staining. Results：In the normal control group, the positive of survivin was 0%. In the carcinoma group, 34 cases were positive in the survivin staining, the positive rate was 77.3%, which was higher tban that in the normal control group. The positive rate in the Ⅰ grade group was 56.3% （9/16）, 87.5% （ 11/16） in Ⅱ grade group, 91.7%（11/12） in the Ⅲ grade group. The positive rate was 79.2% in the superficial type group and it was 75.0% in the invasive type group. According to correlation analysis, the expression of survivinwas related to the grade of tumor, not with clinical stage. Conclusions： The abnormal high expression of survivin plays an im portant role in the occurrence of bladder transitional cell carcinomas. The expression of survivin was an effectively index in the diagnosis and prognosis of transitional cell carcinonma of bladder.